Zimmer Biomet market cap ZBH
Share price times shares outstanding: what the whole company sells for, since 2009.
- Today, Oct 23, 2026
- $18.8B
- Highest close in our data
- $35.8B
- Apr 2021
Zimmer Biomet is worth $18.8B at the close on Oct 23, 2026, at $98.56 a share.
That is down 8% over the last year and down 35% over five years.
Its highest close in our data was $35.8B in Apr 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $18.8B | $15.9B | $19.3B | +5% |
| 2025 | $18B | $17.5B | $22.3B | −15% |
| 2024 | $21.3B | $20.8B | $27.1B | −16% |
| 2023 | $25.4B | $21.6B | $30.4B | −5% |
| 2022 | $26.8B | $21.5B | $27.1B | +4% |
| 2021 | $25.7B | $24.5B | $35.8B | −17% |
| 2020 | $31B | $17.2B | $32B | +4% |
| 2019 | $29.9B | $20.6B | $30B | +47% |
| 2018 | $20.3B | $19.7B | $26B | −14% |
| 2017 | $23.7B | $20.4B | $25.9B | +18% |
| 2016 | $20.1B | $18.1B | $25.4B | −1% |
| 2015 | $20.3B | $16.8B | $21.2B | +8% |
| 2014 | $18.8B | $14.9B | $18.9B | +21% |
| 2013 | $15.5B | $11.6B | $15.5B | +40% |
| 2012 | $11B | $9.4B | $11.5B | +19% |
| 2011 | $9.3B | $8.2B | $12.8B | −10% |
| 2010 | $10.3B | $9.2B | $12.8B | −16% |
| 2009 | $12.2B | $9.8B | $12.5B | n/a |
Against its peers
Companies in Medical - Devices nearest Zimmer Biomet's size, closest first, today.
| Company | Market cap |
|---|---|
| ZBHZimmer Biomet | $18.8B |
| DXCMDexCom | $29.4B |
| GEHCGE HealthCare Technologies | $32.3B |
| EWEdwards Lifesciences | $51.3B |
| BSXBoston Scientific | $66.2B |
| LIVNLivaNova | $4.5B |
| ITGRInteger | $4.3B |
| SYKStryker | $117.8B |
| MDTMedtronic | $122B |
| TMDXTransMedics | $2.5B |
| ABTAbbott Laboratories | $179.4B |
| Peer median | $41.8B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Zimmer Biomet
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.